ADCs from a decade-old Singapore biotech find new life with $187M

Kyle LaHucik

Senior Reporter

Frazier Life Sciences and a cadre of well-known biotech investors are coming together for a new startup in the antibody-drug conjugates field, an area of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ADCs from a decade-old Singapore biotech find new life with $187M

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

Genentech vet launches ADC startup with $20M

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

AD­Cs from a decade-old Sin­ga­pore biotech find new life with $187M

Senior Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

ADCs from a decade-old Singapore biotech find new life with $187M